2011 INDUCTEE D. Lorne Tyrrell, MD PhD Infectious Disease, Allergy & Immunity, Leadership in Organizational Development

Lorne Tyrrell inducted into the Canadian Medical Hall of Fame

London, Ontario

Dr. Tyrrell’s hepatitis studies extended to hepatitis C, where, with two colleagues, he developed another model system, an immunodeficient mouse with a humanized liver

Hundreds of compounds could now be tested as potential drugs against hepatitis C.

Lamivudine was licensed in Canada as Heptovir

The drug was shown to forestall HBV’s life-shortening complications, transmission, and reinfection after liver transplantation.

Began his 10-year term as Dean of Medicine at the University of Alberta

Under his leadership, medical research space tripled, the Mazankowski Heart Institute was created, and Dentistry and Indigenous MD programs were reviewed.

Early Lamivudine drug trials began

Lamivudine was discovered to decrease the viral count in the circulating blood by over 99%.

Dr. Lorne Tyrrell and his team discovered a new series of anti-viral compounds that had therapeutic potential for HBV treatment

Lamivudine became the first oral anti-HBV drug for the treatment of HBV carriers.

Returned to the University of Alberta as an Associate Professor in Infectious Disease and Biochemistry

He later took on more leadership roles as the Director of Infectious Disease and the Chair of the Department of Medical Microbiology and Infectious Disease.

After completing his PhD, pursued post-doctoral training

He became a fellow of infectious disease at the University of Alberta and then travelled to Sweden to study at the Karolinska Institute in Stockholm.